Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 16/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9659093 | 1.00 | OPRK1 (0.74) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9450317 | 1.00 | OPRK1 (0.74) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9659108 | 1.00 | OPRK1 (0.74) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL7942420 | 1.00 | OPRK1 (0.74) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9450189 | 1.00 | OPRK1 (0.74) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9659100 | 1.00 | OPRK1 (0.74) | OPRK1CYP2D6OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL8008206 | 0.99 | OPRK1 (0.72) | OPRK1CYP2D6OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL7640563 | 0.99 | OPRK1 (0.72) | OPRK1CYP2D6OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL29878303 | 0.99 | OPRK1 (0.72) | OPRK1CYP2D6OPRM1OPRD1 | |
| Hydrochloric Acid SCHEMBL29877998 | 0.99 | OPRK1 (0.72) | OPRK1CYP2D6OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2021-09-07 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2019-11-21 | — | — | US | disclosed |
| EP-3013812-B1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-01-18 | — | — | US | disclosed |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2016-05-26 | — | — | US | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
| US-7642274-B2 | Inhibitor of pain threshold decrease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-20070117853-A1 | Inhibitor of pain threshold decrease | SANTEN PHARMACEUTICAL CO., LTD (JP) | 2007-05-24 | — | — | US | disclosed |
| EP-1642590-A1 | PAIN THRESHOLD FALL INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-5232978-A | 1-(2-arylethyl)-pyrrolidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-08-03 | — | — | US | disclosed |
| EP-0483580-A2 | 1-(2-Arylethyl)-pyrrolidine | MERCK PATENT GmbH (DE) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117853-A1 | Inhibitor of pain threshold decrease | OPRD1, OPRK1, OPRL1 | OPRK1 2/4885CYP2D6 3114/4885OPRM1 4/4885 |
| US-20160145245-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 322/4885OPRM1 3/4885 |
| US-20190352291-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 322/4885OPRM1 3/4885 |
| US-20030144272-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 659/4885OPRM1 3/4885 |
| US-11111214-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885CYP2D6 341/4885OPRM1 3/4885 |
| US-20180016266-A1 | KAPPA OPIOID AGONISTS AND USES THEREOF | OPRK1, OPRD1, OPRL1 | OPRK1 1/4885CYP2D6 371/4885OPRM1 4/4885 |
| US-10407416-B2 | Kappa opioid agonists and uses thereof | OPRK1, OPRD1, OPRL1 | OPRK1 1/4885CYP2D6 371/4885OPRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.